Compounds and methods for treating influenza
View Patent ↗This invention is directed to methods for treating and preventing influenza infection by inhibiting influenza virus HA maturation processes employing compounds of formula I. It is also directed to combinations for treating and preventing influenza infection comprising compounds of formula I and other agents.
1. A method of treating a patient suffering from an influenza-like illness comprising administering to the patient a therapeutically effective amount of a compound of formula I
or a pharmaceutically acceptable salt thereof, wherein at least one of R 1 , R 2 , and R 3 is OH or an ester thereof; R 4 , R 5 , and the remainder of R 1 , R 2 , and R 3 , are H; and R 6 is NO 2 and R 9 is H,
wherein the influenza-like illness comprises one or more respiratory symptoms selected from the group consisting of erythematous oropharynx, hypertrophic tonsils, nasal congestion, rhonchi and adenomegaly, wherein the compound of formula I is administered at a dose selected from 100 mg to 600 mg.
2. The method of claim 1 , wherein the patient does not test positive for Adenovirus, RSV, Influenza A, and Parainfluenza 1.
3. The method of claim 1 , wherein R 1 is OH or OC(═O)Q, where Q is R 7 , OR 7 , or NHR 7 ; R 7 is lower alkyl, aryl, or heteroaryl; R 4 , R 5 , R 2 , and R 3 , are H.
4. The method of claim 1 , wherein the compound of formula I is selected from the group consisting of nitazoxanide, tizoxanide and mixtures thereof, or a pharmaceutically acceptable salt thereof.
5. The method of claim 4 , wherein the compound of formula I is nitazoxanide, or a pharmaceutically acceptable salt thereof.
6. The method of claim 4 , wherein the patient is a human.
7. The method of claim 6 , wherein the patient is under 12 years old.
8. The method of claim 6 , wherein the patient is at least 12 years old.
9. The method of claim 1 , wherein the influenza-like illness comprises two or more respiratory symptoms selected from the group consisting of erythematous oropharynx, hypertrophic tonsils, nasal congestion, rhonchi and adenomegaly.
10. The method of claim 9 , wherein the compound of formula I is selected from the group consisting of nitazoxanide, tizoxanide and mixtures thereof, or a pharmaceutically acceptable salt thereof.
11. The method of claim 10 , wherein the compound of formula I is nitazoxanide, or a pharmaceutically acceptable salt thereof.
12. The method of claim 9 , wherein the patient is a human.
13. The method of claim 12 , wherein the patient is under 12 years old.
14. The method of claim 12 , wherein the patient is at least 12 years old.
15. The method of claim 1 , wherein the influenza-like illness comprises three or more respiratory symptoms selected from the group consisting of erythematous oropharynx, hypertrophic tonsils, nasal congestion, rhonchi and adenomegaly.
16. The method of claim 15 , wherein the compound of formula I is selected from the group consisting of nitazoxanide, tizoxanide and mixtures thereof, or a pharmaceutically acceptable salt thereof.
17. The method of claim 16 , wherein the compound of formula I is nitazoxanide, or a pharmaceutically acceptable salt thereof.
18. The method of claim 16 , wherein the patient is a human.
19. The method of claim 18 , wherein the patient is under 12 years old.
20. The method of claim 18 , wherein the patient is at least 12 years old.
21. The method of claim 1 , wherein the compound of formula I is administered at a dose selected from the group consisting of: 300 mg and 600 mg.
22. The method of claim 1 , wherein the compound of formula I is administered twice daily at a dose selected from the group consisting of: 300 mg and 600 mg.
23. The method of claim 1 , wherein the compound of formula I is administered twice daily at a dose selected from the group consisting of: 300 mg and 600 mg.
24. The method of claim 1 , wherein the compound of formula I is administered twice daily at a dose selected of 300 mg.
25. The method of claim 24 , wherein the compound is not administered for more than five days.
26. The method of claim 1 , wherein the compound of formula I is nitazoxanide and wherein the nitazoxanide is administered twice daily.
27. The method of claim 26 , wherein the nitazoxanide is administered as a modified release bi-layer tablet.
28. The method of claim 1 , wherein the compound of formula I is administered as a mono-therapy.
29. The method of claim 28 , wherein the compound of formula I is nitazoxanide or a pharmaceutically acceptable salt thereof.
30. The method of claim 1 , wherein the compound of formula I is nitazoxanide or a pharmaceutically acceptable salt thereof.
31. The method of claim 1 , wherein the compound of formula I is administered twice daily at a dose selected of 600 mg.